Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?

Introduction: Tildrakizumab, a humanized monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), has shown promise in the management of moderate-to-severe plaque psoriasis, offering potential improvements in clinical outcomes and quality of life. Objectives: The study aimed to ident...

Full description

Saved in:
Bibliographic Details
Main Authors: Eugenia Veronica Di Brizzi (Author), Stefano Caccavale (Author), Roberta Di Caprio (Author), Francesco Cusano (Author), Rocco De Pasquale (Author), Valeria Falcomatà (Author), Caterina Foti (Author), Claudia Giofrè (Author), Emanuela Gubinelli (Author), Giampiero Mazzocchetti (Author), Massimiliano Nicolini (Author), Giovanni Palazzo (Author), Leonardo Pescitelli (Author), Rosa Valentina Puca (Author), Oriele Sarno (Author), Anna Balato (Author)
Format: Book
Published: Mattioli1885, 2024-10-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available